Lecture 13: Estrogens Flashcards

1
Q

Requirements of estrogen activity

A

-aromaticity in A ring
-hydroxyl at 3 position
-17B OH group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Hydroxyl of estrogen

A

-can be masked as ether derivative
-ether hydrolyzed in vivo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

17a-ethynyl substituent on estrogen

A

-blocks metabolism
-allows oral activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

17B OH group of estrogen

A

-required
-can be temporarily blocked by ester for drug delivery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

16-OH on estrogen

A

-decreases activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

17a-alkylated estrogens

A

-prevents conversion to ESTRONE
=enhances bioavailability
=inc half life
-3-alkylated ether is dealkylated in vivo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

17a-alkylated estrogen examples

A

-ethinyl estradiol
-mestranol
-quinestrol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Estrogenic esters

A

-esterification decreases solubility
=slow absorption
=prolong action
=less frequent injections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Estrogenic ester examples

A

-estradiol valerate
-estradiol cypionate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

conjugated estrogens

A

-usually collected from pregnant horse piss
-mixture of estrogens
-50-60% estrone sulfate
-20-30% equilin sulfate
-other estrogenic substances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Nonsteroidal estrogen structure requirements

A

-OH group
-rigid core
-hydroxyl (enhances)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Nonsteroidal estrogen structure requirements for ANTAgonist activity

A

-amine side chain
-aromatic ring

-both interfere with helix-12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Non-steroidal estrogens

A

-diethylstilbestrol
-chlorotrianisene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

diethylstilbestrol

A

-non-steroidal estrogen
-used 1940s-70s to prevent miscarriage
-increased risk of vaginal adenocarcinoma in women exposed in utero
-used in advanced prostatic cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

chlorotrianisene use

A

-postpartum breast engorgement
-menopause symptoms
-prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Selective estrogen receptor modulators (SERM)

A

-“designer estrogens”
-partial estrogen agonists
-estrogenic or antiestrogenic depending on tissue
-mostly nonsteroidal estrogens
-maybe alternative for estrogen replacement therapy

16
Q

Structural basis of SERM activity

A

-bind ligand binding domain
-Helix 12 conformation BLOCKS coactivator from binding

17
Q

Tamoxifen

A

-prodrug, oxidized in vivo
-partial estrogen agonist

18
Q

partial estrogen agonist

A

-block potent estrogen agonists from binding
-change helix12 conformation

19
Q

Tamoxifen antiestrogenic actions

A

-treat breast cancer
-prevent breast cancer

20
Q

tamoxifen estrogenic actions

A

-weak estrogen agonist at endometrial cells
-inc risk for thromboembolic events
-prevents osteoporosis

21
Q

Toremifene

A

-similar structure to tamoxifen
-SERM
-treat advanced breast cancer

22
Q

Ospemifene

A

-structurally similar to toremifene
-SERM
-estrogenic effects on vaginal epithelium
-treat dysparenunia in post-menopausal women

23
Q

Raloxifene

A

-SERM
-partial agonist
-tissue-specific activity

24
Q

Raloxifene estrogen actions

A

-prevent osteoporosis in postmen women
-decrease LDL
-inc risk of blood clots

25
Q

Raloxifene antiestrogen actions

A

-dec risk of breast cancer
-does NOT stimulate endometrial cells
-may cause hot flashes

26
Q

Bazedoxifene

A

-raloxifene analog

27
Q

Clomiphene

A

-SERM, parial agonist
-inc FSH and LH secretion (inhibits feedback)
-stimulate ovulation in women with amenorrhea and ovulatory dysfunction (PCOS)

28
Q

polycystic ovary syndrome (PCOS)

A

-7% of women
-gonadotropin-dependent ovarian hyperandrogenism
-anovulation and infertility

29
Q

Fulvestrant

A

-SERD (downregulator)
-pure estrogen ANTAgonist for breast cancer treatment
-more effective than SERM in patients resistant to tamoxifen

30
Q

Aromatase inhibitors

A

-block synthesis of estrogens
-effective in breast cancer patients resistant to tamoxifen
-ovulation induction (off-label)
-gynecomastia

31
Q

Aromatase inhibitor examples

A

-anastrozole
-letrozole
-exemestane